Susquehanna International Group, LLP Lineage Cell Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
A detailed history of Susquehanna International Group, LLP transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 547,242 shares of LCTX stock, worth $946,728. This represents 0.0% of its overall portfolio holdings.
Number of Shares
547,242
Previous 236,109
131.78%
Holding current value
$946,728
Previous $106,000
368.87%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding LCTX
# of Institutions
141Shares Held
106MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$85.7 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$16.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$14.7 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$11.7 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$9.33 Million6.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $294M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...